ERBB2 and breast carcinoma: In addition, a small observational study of 51 patients with non-metastatic HER2-positive breast cancer, published after this scoping review was completed, did not identify ADAs with IV (n = 24; median of 13 treatment cycles) or SC trastuzumab (n = 27; 10 cycles) [65].